FARMERS & MERCHANTS TRUST Co OF LONG BEACH Has $767,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% in the 1st quarter, Holdings Channel reports. The institutional investor owned 1,420 shares of the company’s stock after selling 90 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in IDEXX Laboratories were worth $767,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of IDXX. Norges Bank acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $512,190,000. International Assets Investment Management LLC grew its position in shares of IDEXX Laboratories by 51,631.3% during the 4th quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock worth $304,075,000 after buying an additional 546,775 shares during the period. Capital Research Global Investors acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $135,910,000. TD Asset Management Inc grew its position in shares of IDEXX Laboratories by 178.8% during the 4th quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock worth $144,317,000 after buying an additional 166,751 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $78,001,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.2 %

IDXX traded up $0.73 during trading on Tuesday, reaching $477.13. The company had a trading volume of 96,473 shares, compared to its average volume of 471,883. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The business’s fifty day moving average price is $501.58 and its 200 day moving average price is $526.59. The company has a market cap of $39.41 billion, a P/E ratio of 46.12, a PEG ratio of 3.97 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Barclays decreased their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Finally, Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $586.63.

Insider Transactions at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the sale, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.18% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.